Preclinical and clinical studies of anticancer agent-incorporating polymer micelles

Cancer Science
Yasuhiro Matsumura, K Kataoka

Abstract

The size of anticancer agent-incorporating micelles can be controlled within the diameter range of 20-100 nm to ensure that they do not penetrate normal vessel walls. With this development, it is expected that the incidence of drug-induced side-effects may be decreased owing to the reduced drug distribution in normal tissue. Micelle systems can also evade non-specific capture by the reticuloendothelial system because the outer shell of a micelle is covered with polyethylene glycol. Consequently, a polymer micelle carrier can be delivered selectively to a tumor by utilizing the enhanced permeability and retention effect. Moreover, a water-insoluble drug can be incorporated into polymer micelles. Presently, several anticancer agent-incorporating micelle carrier systems are under preclinical and clinical evaluation. Furthermore, nucleic acid-incorporating micelle carrier systems are also being developed.

References

Jul 11, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B WeissB Leyland-Jones
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyR C Donehower
Apr 13, 1995·The New England Journal of Medicine·E K Rowinsky, R C Donehower
Jan 1, 1994·Pharmacotherapy·D R Kohler, B R Goldspiel
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·V PinzaniP Balmès
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergG I Rodriguez
Apr 1, 1996·Urology·S B Malkowicz, D J Vaughn
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C WasserheitJ Speyer
Mar 4, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·H MaedaK Hori
Feb 7, 2001·Cancer Investigation·D KhayatD Coeffic
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Jan 11, 2002·The New England Journal of Medicine·Kazumasa NodaUNKNOWN Japan Clinical Oncology Group
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Diane C BodurkaDavid M Gershenson
Feb 6, 2003·British Journal of Cancer·S NegoroUNKNOWN CPT-11 Lung Cancer Study Group West
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jim CassidyEduardo Díaz-Rubio
Dec 14, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Horacio CabralKazunori Kataoka
Apr 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GotoK Shirao
Jul 4, 2006·Pharmacology & Therapeutics·Nobuhiro Nishiyama, Kazunori Kataoka
Feb 20, 2007·Proceedings of the National Academy of Sciences of the United States of America·Mitsunobu R KanoKohei Miyazono
Jul 14, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Horacio CabralKazunori Kataoka
Feb 4, 2009·International Journal of Cancer. Journal International Du Cancer·Jun-ichiro KurodaYasuhiro Matsumura

❮ Previous
Next ❯

Citations

Mar 3, 2010·Pharmaceutical Research·Helen LeeChristine Allen
Aug 21, 2010·Pharmaceutical Research·Chris OerlemansWim E Hennink
Dec 25, 2010·Pharmaceutical Research·Wassana WijagkanalanMitsuru Hashida
May 27, 2011·Pharmaceutical Research·Melissa D HowardYounsoo Bae
Oct 29, 2011·Pharmaceutical Research·Shanjida AkterYounsoo Bae
Feb 26, 2013·Cancer Letters·Farrukh AqilManicka V Vadhanam
Aug 27, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anita BogomilovaLaura Schreiner
Jul 16, 2011·Accounts of Chemical Research·Horacio CabralKazunori Kataoka
Dec 5, 2013·Chemical Reviews·Bethany Powell Gray, Kathlynn C Brown
Oct 7, 2011·Molecular Pharmaceutics·Ruth Duncan, Rogerio Gaspar
Jun 10, 2011·Chemical Communications : Chem Comm·Ghareb M SolimanAshok Kakkar
Jun 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Horacio CabralKazunori Kataoka
Sep 26, 2013·Proceedings of the National Academy of Sciences of the United States of America·Lin ZhuVladimir P Torchilin
Jun 29, 2013·Journal of Biomaterials Science. Polymer Edition·Longlong ChangAnjie Dong
Jan 7, 2011·Science Translational Medicine·Mami MurakamiKazunori Kataoka
Jun 7, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William C ZamboniPiotr Grodzinski
Apr 27, 2011·Molecular Cancer Therapeutics·Eric A MurphyDavid A Cheresh
Oct 12, 2012·International Journal of Nanomedicine·Hong YuanFu-Qiang Hu
Jan 14, 2012·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Andreas Müller-SchiffmannCarsten Korth
Dec 7, 2010·Nanomedicine·Ngoc Trinh HuynhCatherine Passirani
Jul 29, 2010·Nanomedicine·Sarah R MacEwanAshutosh Chilkoti
Jul 1, 2010·Therapeutic Delivery·Evren H GokceEliana B Souto
Apr 24, 2014·Japanese Journal of Clinical Oncology·Yasuhiro Matsumura
Nov 21, 2013·Pharmaceutical Research·Matthew DickersonYounsoo Bae
Mar 29, 2014·BioMed Research International·Su-Eon JinSoon-Sun Hong
Aug 27, 2013·Journal of Materials Science. Materials in Medicine·Victor R de la Rosa
Dec 24, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Hiroyuki NakamuraHiroshi Kiwada
May 23, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Xin TianJun Fang
Jul 6, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Atul KolateAmbikanandan Misra
Sep 6, 2011·Annual Review of Medicine·Andrew Z WangOmid C Farokhzad
Jun 24, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hailiang WuKazunori Kataoka
Nov 25, 2014·Therapeutic Delivery·Salma MohamedKhaled Greish
Feb 18, 2016·Cancer Chemotherapy and Pharmacology·Shahana Dilruba, Ganna V Kalayda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Landau-Kleffner Syndrome

Landau Kleffner syndrome (LKS), also called infantile acquired aphasia, acquired epileptic aphasia, or aphasia with convulsive disorder, is a rare childhood neurological syndrome characterized by the sudden or gradual development of aphasia (the inability to understand or express language) and an abnormal electroencephalogram. Discover the latest research on LKS here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.